Acrivon Therapeutics Net Income Over Time
| ACRV Stock | 1.69 0.11 6.96% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Acrivon Therapeutics Performance and Acrivon Therapeutics Correlation. What growth prospects exist in Biotechnology sector? Can Acrivon capture new markets? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. Valuation analysis balances hard financial data with qualitative growth assessments. While each Acrivon Therapeutics valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Understanding Acrivon Therapeutics requires distinguishing between market price and book value, where the latter reflects Acrivon's accounting equity. The concept of intrinsic value - what Acrivon Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Market sentiment, economic cycles, and investor behavior can push Acrivon Therapeutics' price substantially above or below its fundamental value.
Understanding that Acrivon Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Acrivon Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Acrivon Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Acrivon Therapeutics and related stocks such as Pmv Pharmaceuticals, Relmada Therapeutics, and Vaxart Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMVP | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (25.4 M) | (34.4 M) | (57.8 M) | (73.3 M) | (69 M) | (58.7 M) | (52.8 M) | (55.5 M) |
| RLMD | (12.1 K) | (12.1 K) | (12.1 K) | (45 K) | (20.8 M) | (20.8 M) | (3 M) | (6.3 M) | (9 M) | (15 M) | (59.5 M) | (125.8 M) | (157 M) | (98.8 M) | (80 M) | (72 M) | (75.6 M) |
| VXRT | 1000 K | (4.5 M) | (8.7 M) | (8.9 M) | (11 M) | (19.1 M) | (25.4 M) | (12.5 M) | (18 M) | (18.6 M) | (32.2 M) | (70.5 M) | (107.8 M) | (82.5 M) | (66.9 M) | (60.3 M) | (57.2 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| RPTX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (14.3 M) | (27.2 M) | (53.4 M) | (106.9 M) | (29 M) | (93.8 M) | (84.7 M) | (76.2 M) | (80 M) |
| TCRX | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (26.1 M) | (48.6 M) | (66.2 M) | (89.2 M) | (127.5 M) | (114.7 M) | (109 M) |
| ATYR | (17.6 M) | (17.6 M) | (17.6 M) | (20 M) | (24.4 M) | (48 M) | (57.9 M) | (48.2 M) | (34.5 M) | (23.6 M) | (16.2 M) | (33.8 M) | (45.3 M) | (50.4 M) | (64 M) | (57.6 M) | (60.5 M) |
| CBUS | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (12.1 M) | (26 M) | (27.9 M) | (39.6 M) | (44.8 M) | (29.2 M) | (16.9 M) | (267.6 M) | (251.4 M) | (226.2 M) | (214.9 M) |
| BMEA | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (5.3 M) | (41.2 M) | (80 M) | (117.3 M) | (138.4 M) | (124.6 M) | (118.4 M) |
| UNCY | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.3 M) | (2.5 M) | (10.6 M) | (18.1 M) | (30.5 M) | (36.7 M) | (33.1 M) | (31.4 M) |
Acrivon Therapeutics and related stocks such as Pmv Pharmaceuticals, Relmada Therapeutics, and Vaxart Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Acrivon Therapeutics financial statement analysis. It represents the amount of money remaining after all of Acrivon Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Acrivon Therapeutics Common | ACRV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 480 Arsenal Way, |
| Exchange | NASDAQ Exchange |
null 1.69
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.